2m 2m 2m 2m 2m 2m 2m
- $34.0MMarket Cap
- -52.67%1-Year Change
- Medical DevicesIndustry
Vivos (RDGL)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 42
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Vivos Inc Summarizes Progress in its Animal Therapy Division
Vivos Inc.'s IsoPet division achieved 1,200% year-over-year growth in administered therapies from 2024 to 2025, with over 100 treatments safely performed across various animal species. The company expanded its certified clinic network to 17 locations by year-end 2025, including new certifications at Sun City Veterinary Surgery Center in Texas and University of Florida Small Animal Hospital. The division plans to implement profitability-focused initiatives in Q1 2026 while continuing clinic expansion, with multiple clinical publications anticipated to support veterinary adoption.
12/22/2025, 12:56 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.
Key Executives
- Michael K. Korenko
- Brad Allan Weeks
- David J. Swanberg
- Carlton Cadwell
- Jim Duncan
Current Ownership Distribution
- Other447.4M (90.59%)
- Insiders46.4M (9.39%)
- Institutions126,000 (0.03%)
- Mutual Funds0 (0.00%)